Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

bispecific antibody AGEN1223

A bispecific antibody that simultaneously binds to two different and as of yet undisclosed antigens co-expressed specifically on tumor-infiltrating regulatory T cells (Tregs), with potential immunomodulating and antineoplastic activities. Upon administration, AGEN1223 targets and binds to the two antigens co-expressed specifically on tumor-infiltrating Tregs. This leads to the selective depletion of immunosuppressive Tregs in the tumor microenvironment (TME), while sparing peripheral Tregs and effector T cells, enhancing the overall antitumor response. AGEN1223 may also co-stimulate antigen-specific effector T cells, resulting in tumor cell death.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:AGEN-1223
Code name:AGEN 1223
AGEN1223
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search